Search All UT System Experts

A phase I-II evaluation of veliparib (NSC #737664), topotecan, and filgrastim or pegfilgrastim in the treatment of persistent or recurrent carcinoma of the uterine cervix: An NRG oncology/gynecologic oncology group study

Charles Kunos, Wei Deng, Dawn Dawson, Jayanthi S. Lea, Kristine M. Zanotti, Heidi J. Gray, David P. Bender, Perry P. Guaglianone, Jori S. Carter, Kathleen N. Moore

Research output: Contribution to journal › Article › peer-review

47 Scopus citations

Fingerprint

Dive into the research topics of 'A phase I-II evaluation of veliparib (NSC #737664), topotecan, and filgrastim or pegfilgrastim in the treatment of persistent or recurrent carcinoma of the uterine cervix: An NRG oncology/gynecologic oncology group study'. Together they form a unique fingerprint.

Medicine & Life Sciences